Trans Genic Group
2342.TServices
Filed as TRANS GENIC INC. (2022-06–2024-06)
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥13.2bn | ¥13.0bn | ¥13.1bn | ¥11.4bn | ¥12.6bn | ¥11.0bn |
| Operating income | ¥138m | −¥260m | ¥89m | −¥25m | ¥1.8bn | ¥893m |
| Ordinary income | ¥118m | −¥320m | ¥108m | ¥199m | ¥1.8bn | ¥892m |
| Net income (owners) | −¥77m | −¥1.1bn | ¥4m | −¥410m | ¥1.9bn | ¥546m |
| Total assets | ¥9.7bn | ¥9.6bn | ¥9.8bn | ¥10.7bn | ¥10.4bn | ¥8.9bn |
| Net assets / equity | ¥4.8bn | ¥4.9bn | ¥6.0bn | ¥6.1bn | ¥6.6bn | ¥5.0bn |
| Operating cash flow | ¥26m | ¥94m | −¥392m | −¥1.4bn | ¥1.8bn | ¥1.2bn |
| EPS (basic) | ¥-4.64 | ¥-65.51 | ¥0.24 | ¥-24.32 | ¥109.52 | ¥31.45 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 14
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2026-03-31 | Annual | 195 figures · EDINET |
| 2025-04-01 → 2025-09-30 | Half-year | 71 figures · EDINET |
| 2024-04-01 → 2025-03-31 | AnnualAmended | 200 figures · EDINET |
| 2024-04-01 → 2025-03-31 | Annual | 200 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 71 figures · EDINET |
| 2023-04-01 → 2024-03-31 | Annual | 200 figures · EDINET |
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 49 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 73 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 47 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 202 figures · EDINET |
| 2022-04-01 → 2022-12-31 | Quarterly Q3 | 51 figures · EDINET |
| 2022-04-01 → 2022-09-30 | Quarterly Q2 | 75 figures · EDINET |
| 2022-04-01 → 2022-06-30 | Quarterly Q1 | 49 figures · EDINET |
| 2021-04-01 → 2022-03-31 | Annual | 203 figures · EDINET |
21 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| Drug Discovery Support Business | ¥2.3bn | −¥164m |
| Investments And Consulting Business | ¥10.9bn | ¥480m |
| Adjustments & eliminations | — | −¥177m |
| Total | ¥13.2bn | ¥315m |
Segment names from EDINET member IDs; not mapped to a common taxonomy.